Seoul, South Korea

Chan-Sik Yang

USPTO Granted Patents = 1 

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chan-Sik Yang: Innovator in Cardiovascular Treatment

Introduction

Chan-Sik Yang is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the prevention and treatment of cardiovascular diseases. His innovative work has led to the development of a novel compound that holds promise for improving patient outcomes.

Latest Patents

Chan-Sik Yang holds 1 patent for his invention titled "N-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease." This patent describes a unique N-acylurea derivative that can inhibit platelet aggregation by targeting the activity of talin in the intracellular matrix. The pharmaceutical composition developed from this derivative is aimed at preventing or treating cardiovascular diseases, showcasing its potential therapeutic benefits.

Career Highlights

Throughout his career, Chan-Sik Yang has been associated with several esteemed institutions. He has worked with the Osong Medical Innovation Foundation, Korea University Research and Business Foundation, and Kyungpook National University Industry-Academic Cooperation Foundation. His roles in these organizations have allowed him to advance his research and contribute to significant medical innovations.

Collaborations

Chan-Sik Yang has collaborated with notable colleagues, including Soon Jun Hong and Chung Ho Kim. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the field of cardiovascular treatment.

Conclusion

Chan-Sik Yang's innovative contributions to cardiovascular medicine through his patented N-acylurea derivative highlight his role as a key inventor in this critical area of healthcare. His work continues to pave the way for advancements in treatment options for cardiovascular diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…